Should mutant TP53 be targeted for cancer therapy?

Cell Death & Differentiation, Published online: 24 March 2022; doi:10.1038/s41418-022-00962-9The attributes proposed for mutant TP53 to drive tumour development and possible approaches to target them. Model depicting the three attributes by which mutant TP53 is thought to promote tumour development: loss-of-function (LOF), dominant negative effects (DNE) over wt TP53 and neomorphic gain-of-function (GOF) effects.

Source: Cell Death and Differentiation - March 24, 2022 Category: Cytology Authors: Zilu Wang Andreas Strasser Gemma L. Kelly Source Type: research